JP2016506416A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506416A5 JP2016506416A5 JP2015552058A JP2015552058A JP2016506416A5 JP 2016506416 A5 JP2016506416 A5 JP 2016506416A5 JP 2015552058 A JP2015552058 A JP 2015552058A JP 2015552058 A JP2015552058 A JP 2015552058A JP 2016506416 A5 JP2016506416 A5 JP 2016506416A5
- Authority
- JP
- Japan
- Prior art keywords
- epitope
- influenza
- derived
- immunogenic composition
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 41
- 102000036639 antigens Human genes 0.000 claims description 41
- 108091007433 antigens Proteins 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 34
- 229920001184 polypeptide Polymers 0.000 claims description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 230000002163 immunogen Effects 0.000 claims description 29
- 241000712461 unidentified influenza virus Species 0.000 claims description 13
- 239000000185 hemagglutinin Substances 0.000 claims description 8
- 206010022000 influenza Diseases 0.000 claims description 8
- 101710154606 Hemagglutinin Proteins 0.000 claims description 6
- 241000712431 Influenza A virus Species 0.000 claims description 6
- 241000713196 Influenza B virus Species 0.000 claims description 6
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 6
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 6
- 101710176177 Protein A56 Proteins 0.000 claims description 6
- 101900234398 Influenza B virus Hemagglutinin Proteins 0.000 claims description 5
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 241000710929 Alphavirus Species 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 229920002988 biodegradable polymer Polymers 0.000 claims description 2
- 239000004621 biodegradable polymer Substances 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 4
- 229940124873 Influenza virus vaccine Drugs 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 229940126581 whole-virion vaccine Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 1
- 108010029566 avian influenza A virus hemagglutinin Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361751077P | 2013-01-10 | 2013-01-10 | |
| US61/751,077 | 2013-01-10 | ||
| PCT/EP2014/050414 WO2014108515A1 (en) | 2013-01-10 | 2014-01-10 | Influenza virus immunogenic compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017229215A Division JP2018035195A (ja) | 2013-01-10 | 2017-11-29 | インフルエンザウイルス免疫原性組成物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506416A JP2016506416A (ja) | 2016-03-03 |
| JP2016506416A5 true JP2016506416A5 (https=) | 2017-02-16 |
Family
ID=49956176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552058A Pending JP2016506416A (ja) | 2013-01-10 | 2014-01-10 | インフルエンザウイルス免疫原性組成物およびその使用 |
| JP2017229215A Pending JP2018035195A (ja) | 2013-01-10 | 2017-11-29 | インフルエンザウイルス免疫原性組成物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017229215A Pending JP2018035195A (ja) | 2013-01-10 | 2017-11-29 | インフルエンザウイルス免疫原性組成物およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140193484A1 (https=) |
| EP (1) | EP2943221A1 (https=) |
| JP (2) | JP2016506416A (https=) |
| CN (2) | CN104902925A (https=) |
| AU (2) | AU2014204826A1 (https=) |
| CA (1) | CA2897752A1 (https=) |
| HK (1) | HK1214962A1 (https=) |
| MX (1) | MX2015008847A (https=) |
| RU (1) | RU2015132962A (https=) |
| WO (1) | WO2014108515A1 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3248615A1 (en) | 2010-03-30 | 2017-11-29 | Mount Sinai School of Medicine of New York University | Influenza virus vaccines and uses thereof |
| PL2591114T3 (pl) | 2010-07-06 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Immunizacja dużych ssaków małymi dawkami rna |
| HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
| HUE026646T2 (en) | 2010-07-06 | 2016-07-28 | Glaxosmithkline Biologicals Sa | Preferred liposomes containing lipids of PKA value for delivery of RNA |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3970742T (pt) | 2010-08-31 | 2022-06-27 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para entrega de arn codificador de imunogénio |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| JP2013544504A (ja) | 2010-10-11 | 2013-12-19 | ノバルティス アーゲー | 抗原送達プラットフォーム |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| WO2013006838A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| IN2014CN02114A (https=) | 2011-09-20 | 2015-05-29 | Sinai School Medicine | |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| EA201591164A1 (ru) | 2012-12-18 | 2015-11-30 | Икан Скул Оф Медсин Эт Маунт Синай | Вакцины против вируса гриппа и их применение |
| EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| EP3247389A4 (en) | 2015-01-23 | 2019-10-30 | Icahn School of Medicine at Mount Sinai | INFLUENZAVIRUSSCHUTZIMPFPLÄNE |
| KR20180004820A (ko) | 2015-05-15 | 2018-01-12 | 큐어백 아게 | 적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법 |
| AU2016336344A1 (en) | 2015-10-05 | 2018-04-19 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| WO2017070620A2 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| JP2019511255A (ja) | 2016-01-11 | 2019-04-25 | バーンダリ，インク． | マイクロニードル組成物およびそれを使用する方法 |
| CN105664149A (zh) * | 2016-02-24 | 2016-06-15 | 华东理工大学 | 一种多抗原流感通用疫苗及其制备方法 |
| CA3023143A1 (en) | 2016-06-15 | 2017-12-21 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018187706A2 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| JP2020524143A (ja) * | 2017-06-15 | 2020-08-13 | インフェクシャス ディズィーズ リサーチ インスティチュート | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| CA3073020A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| MX2020004151A (es) | 2017-10-30 | 2020-08-13 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos. |
| EP3810634A4 (en) | 2018-06-21 | 2022-07-27 | Icahn School of Medicine at Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| EP3836963A2 (en) * | 2018-08-17 | 2021-06-23 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions and uses thereof |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| JP7513614B2 (ja) | 2018-12-20 | 2024-07-09 | インターベット インターナショナル ベー． フェー． | プライム－ブーストワクチン接種レジメン |
| EP3959216A4 (en) | 2019-04-24 | 2023-01-11 | Icahn School of Medicine at Mount Sinai | ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF |
| EP4061409A4 (en) * | 2019-11-18 | 2023-12-27 | Children's Medical Center Corporation | Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy |
| WO2022016070A1 (en) | 2020-07-16 | 2022-01-20 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
| CA3236959A1 (en) * | 2021-11-08 | 2023-05-11 | Sue-Jean HONG | Self-amplifying rna compositions and methods of use thereof |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2024191777A2 (en) * | 2023-03-10 | 2024-09-19 | National Health Research Institutes | Influenza virus immunogenic composition and method using the same |
| AU2024270076A1 (en) * | 2023-05-10 | 2025-11-27 | Seqirus Inc. | Combination vaccine |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| CA2204254C (en) | 1994-11-17 | 2010-02-16 | Stephen Lewis Hart | Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6090619A (en) | 1997-09-08 | 2000-07-18 | University Of Florida | Materials and methods for intracellular delivery of biologically active molecules |
| TR200200776T2 (tr) | 1999-09-24 | 2002-06-21 | Smithkline Beecham Biologicals S.A. | Burun içi grip virüsü aşısı. |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| JP2004536785A (ja) | 2001-02-23 | 2004-12-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規なワクチン |
| ATE503493T1 (de) | 2001-02-23 | 2011-04-15 | Glaxosmithkline Biolog Sa | Influenza vakzinzusammensetzungen zur intradermaler verabreichung |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| US20040208848A1 (en) * | 2002-12-13 | 2004-10-21 | Smith Jonathan F. | Multi-antigenic alphavirus replicon particles and methods |
| WO2004058166A2 (en) | 2002-12-23 | 2004-07-15 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| CN1791678A (zh) * | 2003-03-20 | 2006-06-21 | 阿尔法瓦克斯公司 | 改进的甲病毒复制子和辅助构建体 |
| US7566458B2 (en) * | 2003-06-16 | 2009-07-28 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase variants |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| US20060024670A1 (en) | 2004-05-18 | 2006-02-02 | Luke Catherine J | Influenza virus vaccine composition and methods of use |
| EP1751289B1 (en) | 2004-05-18 | 2009-01-14 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
| US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| EP3031469B1 (en) * | 2006-06-07 | 2023-08-23 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| WO2008039267A2 (en) * | 2006-07-21 | 2008-04-03 | Pharmexa Inc. | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions |
| NZ575901A (en) * | 2006-09-12 | 2012-04-27 | Alphavax Inc | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
| SG177141A1 (en) | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| US20100015218A1 (en) * | 2007-02-16 | 2010-01-21 | Vasant Jadhav | Compositions and methods for potentiated activity of biologically active molecules |
| EP2173376B1 (en) * | 2007-08-02 | 2015-03-25 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope influenza vaccines |
| WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
| WO2010006144A2 (en) * | 2008-07-11 | 2010-01-14 | Medlmmune, Llc. | Influenza hemagglutinin and neuraminidase variants |
| CA2733147A1 (en) * | 2008-08-06 | 2010-02-11 | Novartis Ag | Microparticles for use in immunogenic compositions |
| US20110300205A1 (en) * | 2009-07-06 | 2011-12-08 | Novartis Ag | Self replicating rna molecules and uses thereof |
| EP4218799A1 (en) * | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
| JO3257B1 (ar) * | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| ES2443952T3 (es) * | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| US9163068B2 (en) * | 2009-11-03 | 2015-10-20 | The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer | Influenza virus recombinant proteins |
| ES2536429T3 (es) * | 2010-01-24 | 2015-05-25 | Novartis Ag | Micropartículas de polímero biodegradables irradiadas |
| HUE047796T2 (hu) * | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
| US9770463B2 (en) * | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| EP2590625B1 (en) * | 2010-07-06 | 2017-09-20 | GlaxoSmithKline Biologicals SA | Cationic oil-in-water emulsions |
| HUE026646T2 (en) | 2010-07-06 | 2016-07-28 | Glaxosmithkline Biologicals Sa | Preferred liposomes containing lipids of PKA value for delivery of RNA |
| AU2011276328C1 (en) * | 2010-07-06 | 2016-01-21 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
| PL2591114T3 (pl) * | 2010-07-06 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Immunizacja dużych ssaków małymi dawkami rna |
| US9192661B2 (en) * | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| RS63817B1 (sr) | 2010-07-06 | 2023-01-31 | Glaxosmithkline Biologicals Sa | Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk |
| PT3970742T (pt) | 2010-08-31 | 2022-06-27 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para entrega de arn codificador de imunogénio |
| ES2727583T3 (es) | 2010-08-31 | 2019-10-17 | Glaxosmithkline Biologicals Sa | Lípidos adecuados para la administración liposómica de ARN que codifica proteínas |
| RS63890B1 (sr) | 2010-08-31 | 2023-02-28 | Glaxosmithkline Biologicals Sa | Mali lipozomi za isporuku rnk koja kodira imunogen |
| US20130164289A1 (en) * | 2010-09-09 | 2013-06-27 | Virginia Commonwealth University | Human cytomegalovirus vaccine |
| JP2013544504A (ja) * | 2010-10-11 | 2013-12-19 | ノバルティス アーゲー | 抗原送達プラットフォーム |
| AU2012211278B2 (en) * | 2011-01-26 | 2016-11-10 | Glaxosmithkline Biologicals Sa | RSV immunization regimen |
| DK2707385T3 (da) * | 2011-05-13 | 2017-11-20 | Glaxosmithkline Biologicals Sa | RSV-F-præfusionsantigener |
| SG10201605512WA (en) * | 2011-07-06 | 2016-09-29 | Novartis Ag | Oil-in-water emulsions that contain nucleic acids |
| US20140141070A1 (en) | 2011-07-06 | 2014-05-22 | Andrew Geall | Liposomes having useful n:p ratio for delivery of rna molecules |
| US11058762B2 (en) * | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| WO2013006838A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| CA2840965C (en) | 2011-07-06 | 2021-03-02 | Novartis Ag | Cationic oil-in-water emulsions |
| EP3508220A1 (en) * | 2011-08-31 | 2019-07-10 | GlaxoSmithKline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding rna |
| BR112014008694A2 (pt) * | 2011-10-11 | 2017-06-20 | Novartis Ag | moléculas de ácido nucleico policistrônico recombinante |
| WO2013054199A2 (en) * | 2011-10-12 | 2013-04-18 | Novartis Ag | Cmv antigens and uses thereof |
| US9504747B2 (en) * | 2013-03-08 | 2016-11-29 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
-
2014
- 2014-01-10 EP EP14700356.0A patent/EP2943221A1/en not_active Withdrawn
- 2014-01-10 WO PCT/EP2014/050414 patent/WO2014108515A1/en not_active Ceased
- 2014-01-10 CN CN201480004387.6A patent/CN104902925A/zh active Pending
- 2014-01-10 CN CN201811056155.1A patent/CN109045294A/zh active Pending
- 2014-01-10 AU AU2014204826A patent/AU2014204826A1/en not_active Abandoned
- 2014-01-10 JP JP2015552058A patent/JP2016506416A/ja active Pending
- 2014-01-10 HK HK16102971.1A patent/HK1214962A1/zh unknown
- 2014-01-10 US US14/152,397 patent/US20140193484A1/en not_active Abandoned
- 2014-01-10 MX MX2015008847A patent/MX2015008847A/es unknown
- 2014-01-10 RU RU2015132962A patent/RU2015132962A/ru not_active Application Discontinuation
- 2014-01-10 CA CA2897752A patent/CA2897752A1/en not_active Abandoned
-
2017
- 2017-11-29 JP JP2017229215A patent/JP2018035195A/ja active Pending
-
2018
- 2018-11-13 AU AU2018260983A patent/AU2018260983A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506416A5 (https=) | ||
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| WO2016109792A3 (en) | Novel multivalent nanoparticle-based vaccines | |
| JP2019526580A5 (https=) | ||
| JP2018523668A5 (https=) | ||
| WO2020035609A3 (en) | Immunogenic compositions and uses thereof | |
| JP2014503206A5 (https=) | ||
| JP2019530462A5 (https=) | ||
| JP2016539946A5 (https=) | ||
| JP2014534202A5 (https=) | ||
| FI4023249T3 (fi) | Nukleiinihapporokotteita | |
| EA201990718A1 (ru) | Векторы аденовируса собачьих | |
| JP2017158561A5 (https=) | ||
| CN106659777A8 (zh) | 免疫原性组合产品 | |
| JP2014532620A5 (https=) | ||
| JP2015522540A5 (https=) | ||
| JP2009539965A5 (https=) | ||
| CY1125681T1 (el) | Εμβολια κατα του ιου της γριπης και χρησεις αυτων | |
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| JP2020528911A5 (https=) | ||
| JP2017524682A5 (https=) | ||
| JP2016520530A5 (https=) | ||
| FI3656395T3 (fi) | Menetelmiä ja koostumuksia suojaavan immuniteetin aikaansaamiseksi filovirusinfektiota vastaan | |
| JP2019531293A5 (https=) | ||
| Fisher et al. | Virus-derived immunostimulatory RNA induces type I IFN-dependent antibodies and T-cell responses during vaccination |